InvestorsHub Logo
Followers 4
Posts 1198
Boards Moderated 0
Alias Born 10/03/2015

Re: DewDiligence post# 1261

Monday, 01/11/2016 2:40:38 PM

Monday, January 11, 2016 2:40:38 PM

Post# of 3021
ENTA is planning a EDP-239 + EDP-494 combo, their version of Havoni

"Enanta has also discovered EDP-239, an NS5A inhibitor for HCV infection. EDP-239 has successfully completed phase 1 studies in 2015, including a proof-of-concept study, but its further development will depnd upon its potential utility as an additional component of an EDP-494 containing therapy, which will be determined after early clinical trials of EDP-494"
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News